
浏览全部资源
扫码关注微信
1.湖南中医药大学 中医学院,中医诊断学湖南省重点实验室,长沙 410208
2.首都医科大学 中医药学院,北京 100069
3.中华中医药学会,北京 100029
李金霞,博士,讲师,从事中医药治疗心血管疾病的研究,E-mail:531249042@qq.com
* 曹洪欣,博士,教授,从事中医药治疗心血管疾病的研究,E-mail:caohx898@163.com
收稿日期:2021-05-27,
网络出版日期:2021-08-12,
纸质出版日期:2021-10-20
移动端阅览
李金霞,宗文静,曹洪欣.温心方对动脉粥样硬化大鼠G1/S细胞周期转换的调控作用[J].中国实验方剂学杂志,2021,27(20):38-45.
LI Jin-xia,ZONG Wen-jing,CAO Hong-xin.Effect of Wenxin Prescription on G1/S Cell Cycle Transformation in Atherosclerosis Rats[J].Chinese Journal of Experimental Traditional Medical Formulae,2021,27(20):38-45.
李金霞,宗文静,曹洪欣.温心方对动脉粥样硬化大鼠G1/S细胞周期转换的调控作用[J].中国实验方剂学杂志,2021,27(20):38-45. DOI: 10.13422/j.cnki.syfjx.20211905.
LI Jin-xia,ZONG Wen-jing,CAO Hong-xin.Effect of Wenxin Prescription on G1/S Cell Cycle Transformation in Atherosclerosis Rats[J].Chinese Journal of Experimental Traditional Medical Formulae,2021,27(20):38-45. DOI: 10.13422/j.cnki.syfjx.20211905.
目的
2
观察温心方对动脉粥样硬化(AS)大鼠第一间歇期/合成期(G
1
/S)细胞周期转换关键靶点的作用,揭示温心方治疗AS的作用机制。
方法
2
无特定病原体(SPF)级Wistar大鼠90只,随机分为正常组6只和造模组84只,模型组给予高脂饲料(4%胆固醇,0.5%胆酸钠,0.2%丙基硫氧嘧啶,10%猪油,5%白糖,80.3%基础饲料)喂养60 d,每7 d腹腔注射40万U·kg
-1
维生素D
3
,连续3次。成模大鼠随机分为模型组、温心方高、中、低剂量组及瑞伐舒他汀组,每组6只,温心方高、中、低剂量组及瑞伐舒他汀组分别给予24,12,6 g·kg
-1
温心方水煎剂及1.8 mg·kg
-1
瑞舒伐他汀灌胃治疗30 d,模型组灌胃等量蒸馏水。治疗后观察各组大鼠一般情况,酶联免疫吸附测定法(ELISA)检测血清高密度脂蛋白胆固醇(HDL-C),低密度脂蛋白胆固醇(LDL-C),总胆固醇(CHO),计算粥样硬化指数(AI),苏木素-伊红染色观察冠状动脉及主动脉病理形态,蛋白免疫印迹法(Western blot)及实时荧光定量聚合酶链式反应(Real-time PCR)检测主动脉E2F转录因子1(E2F1),磷酸化成视网膜细胞瘤蛋白(p-Rb),细胞分裂周期因子25(Cdc25),细胞周期素E(CyclinE),细胞周期素D
1
(CyclinD
1
)蛋白及mRNA表达。
结果
2
与正常组比较,模型组大鼠冠状动脉及主动脉内膜增厚,平滑肌增殖,粥样斑块形成,HDL-C水平显著降低(
P
<
0.01),LDL-C,CHO,AI水平显著升高(
P
<
0.01),主动脉E2F1,Cdc25,p-Rb,CyclinE,CyclinD
1
蛋白及基因表达均有所上升(
P
<
0.05);与模型组比较,温心方各剂量组及瑞伐舒他汀组大鼠冠状动脉及主动脉内膜增生及管腔变窄不明显,LDL-C,CHO,AI水平显著降低(
P
<
0.01),主动脉E2F1,Cdc25,p-Rb,CyclinE,CyclinD
1
蛋白及基因表达均有不同程度的下降(
P
<
0.05)。
结论
2
温心方可显著抑制AS大鼠主动脉G
1
/S细胞周期关键调控蛋白及基因表达,调控G
1
/S细胞周期转换,减轻血管平滑肌及内膜增生。
Objective
2
To observe the effects of Wenxin prescription on the key targets of gap 1/synthesis (G
1
/S) cell cycle transformation in rats with atherosclerosis (AS), and reveal the mechanism of Wenxin prescription in the treatment of AS.
Method
2
Ninety SPF Wistar rats were randomly divided into a normal group (
n
=6) and a modeling group (
n
=84). The rats in the modeling group were fed on a high-fat diet (4% cholesterol, 0.5% sodium cholate, 0.2% propyl thiouracil, 10% lard, 5% sugar, and 80.3% basal feed) for 60 days, and intraperitoneally injected with 400 000 U·kg
-1
vitamin D
3
, once a week for three weeks. The model rats were then randomly divided into a model group, high-dose (24 g·kg
-1
), medium-dose (12 g·kg
-1
), and low-dose (6 g·kg
-1
) Wenxin prescription groups, and a rosuvastatin (1.8 mg·kg
-1
) group. The groups with drug intervention were treated correspondingly by gavage for 30 days. The rats in the model group were administered with an equal volume of distilled water. The general condition of rats was observed after treatment. The levels of high-density lipoprotein cholesterol (HDL-C), low-density lipoprotein cholesterol (LDL-C), and total cholesterol (CHO) were detected by enzyme-linked immunosorbent assay (ELISA), and the atherosclerosis index (AI) was calculated. The pathological morphology of the coronary artery and aorta was observed by hematoxylin-eosin (HE) staining. The protein and mRNA expression of E2F transcription factor 1 (E2F1), phosphorylated retinoblastoma protein (p-Rb), cell division cycle 25 (Cdc25), CyclinE, and CyclinD
1
was detected by Western blot and real-time fluorescence-based quantitative polymerase chain reaction (Real-time-PCR), respectively.
Result
2
Compared with the normal group, the model group showed intima thickening, smooth muscle proliferation, and plaque formation in the coronary artery and aorta, decreased HDL-C (
P
<
0.01), increased LDL-C, CHO, and AI (
P
<
0.01), elevated protein and mRNA expression of E2F1, Cdc25, p-Rb, CyclinE and CyclinD
1
(
P
<
0.05). Compared with the model group, the rosuvastatin group and the Wenxin prescription groups showed slight intimal hyperplasia and lumen narrowing of the coronary artery and aorta, decreased levels of LDL-C, CHO, and AI (
P
<
0.01), and declining protein and mRNA expression of E2F1, Cdc25, p-Rb, CyclinE, and CyclinD
1
to varying degrees (
P
<
0.05).
Conclusion
2
Wenxin prescription can significantly inhibit the expression of key proteins and genes of the G
1
/S cell cycle, regulate G
1
/S cell cycle transformation, and reduce vascular smooth muscle and intimal hyperplasia in AS rats.
中国心血管健康与疾病报告 2019 概要 [J]. 心脑血管病防治 , 2020 , 20 ( 5 ): 437 - 450 .
廖玉华 , 程翔 , 黄恺 , 等 . ASCVD患者逆转斑块他汀治疗专家共识 [J]. 临床心血管病杂志 , 2015 , 31 ( 1 ): 1 - 5 .
HAN J H , HEO K S , MYUNG C S . CIAPIN1 accelerates vascular remodelling via p53 and JAK2-STAT3 regulation in vascular smooth muscle cells [J]. Br J Pharmacol , 2021 , doi: 10.1111/bph.15631 http://dx.doi.org/10.1111/bph.15631 .
于涛 , 曹洪欣 . 胸痹(冠心病)证候演变规律的临床研究 [J]. 中医药信息 , 2004 , 21 ( 3 ): 44 - 46 .
吕洪雪 , 王婷 , 叶小汉 , 等 . 180例动脉粥样硬化患者中医证型特点分析 [J]. 广东医科大学学报 , 2017 , 35 ( 1 ): 96 - 98 .
曹洪欣 , 张华敏 . 痰瘀互结与冠心病发病机理辨识 [J]. 中医药学刊 , 2001 , 19 ( 6 ): 544 - 545 .
李金霞 , 张华敏 , 曹洪欣 . 温阳益心法治疗冠心病冠状动脉狭窄32例临床疗效的回顾性研究 [J]. 中医杂志 , 2019 , 60 ( 9 ): 754 - 759 .
曹洪欣 , 顾江萍 , 龚其森 . 温阳益心法治疗胸痹的临床研究 [J]. 中医药学报 , 2000 , 5 : 10 - 11 .
李金霞 . 温阳益心法治疗冠脉狭窄疗效与机制研究 [D]. 北京 : 中国中医科学院 , 2019 .
李春杰 , 谷素洁 , 曹洪欣 , 等 . 温阳益心法治疗急性冠脉综合征的临床研究 [J]. 中医药学报 , 2011 , 39 ( 4 ): 55 - 57 .
李同达 . 温阳益心活血化痰法对冠状动脉粥样硬化大鼠血管内皮保护作用研究 [D]. 北京 : 中国中医科学院 , 2014 .
张华敏 , 曹洪欣 , 殷惠军 . 温心胶囊对实验性动物粥样硬化血脂及脂质过氧化物的影响 [J]. 中医药学刊 , 2003 , 21 ( 3 ): 396 - 397 .
唐丹丽 , 曹洪欣 , 张华敏 . 温阳益心法对动脉粥样硬化大鼠主动脉MCP-I、NF- κ B表达的影响 [J]. 中国中医基础医学杂志 , 2007 , 13 ( 2 ): 110 - 112 .
张明雪 , 曹洪欣 . 温心胶囊对冠心病心阳虚证大鼠血小板形态MPV,PDW值的影响 [J]. 中药新药与临床药理 , 2005 , 16 ( 1 ): 30 - 33 .
张明雪 , 曹洪欣 . 温阳活血化痰法降低冠心病心阳虚证血小板聚集率的机制探讨 [J]. 中国中西医结合急救杂志 , 2003 , 10 ( 2 ): 84 - 86 .
李金霞 , 曹洪欣 . 基于复杂网络的温心方治疗冠状动脉狭窄机制研究 [J]. 中国中医药信息杂志 , 2019 , 26 ( 6 ): 101 - 105 .
李同达 , 曹洪欣 , 徐慧 , 等 . 冠状动脉粥样硬化大鼠实验动物模型的改进与评价 [J]. 中国实验动物学报 , 2013 , 21 ( 6 ): 32 - 36 .
张荣先 , 莫显刚 , 李伟 , 等 . 血脂控制水平对冠状动脉支架内内膜增生及增生程度的影响 [J]. 重庆医学 , 2018 , 47 ( 3 ): 384 - 386 .
VWOHLSCHLAEGER J , SCHMITZ K J , TAKEDA A , et al . Reversible regulation of the retinoblastoma protein/E2F-1 pathway during "reverse cardiac remodelling" after ventricular unloading [J]. J Heart Lung Transplant , 2010 , 29 ( 1 ): 117 - 124 .
DESVOYES B , GUTIERREZ C . Roles of plant retinoblastoma protein:cell cycle and beyond [J]. EMBO J , 2020 , 39 ( 19 ): e105802 .
ZHANG S , ZHU X , LI G . E2F1/SNHG7/miR-186-5p/MMP2 axis modulates the proliferation and migration of vascular endothelial cell in atherosclerosis [J]. Life Sci , 2020 , 15 ( 257 ): 118013 .
ENDORF E B , QING H , AONO J , et al . Telomerase reverse transcriptase deficiency prevents neointima formation through chromatin silencing of E2F1 target genes [J]. Arterioscler Thromb Vasc Biol , 2017 , 37 ( 2 ): 301 - 311 .
WU T , WU L . The role and clinical implications of the retinoblastoma (RB)-E2F pathway in gastric cancer [J]. Front Oncol , 2021 , 31 ( 11 ): 655630 .
CHI J S , LI J Z , JIA J J , et al . Long non-coding RNA ANRIL in gene regulation and its duality in atherosclerosis [J]. J Huazhong Univ Sci Technolog Med Sci , 2017 , 37 ( 6 ): 816 - 822 .
康建梅 , 丁周莉 , 罗荧荃 , 等 . 自噬相关基因5和细胞周期素E在冠心病中的表达及其临床意义 [J]. 中南大学学报:医学版 , 2020 , 45 ( 1 ): 17 - 23 .
0
浏览量
34
下载量
2
CSCD
关联资源
相关文章
相关作者
相关机构
京公网安备11010802024621